Abstract:GLP-1, an important incretin hormone plays an important role in the regulation of glucose homeostasis. However, the therapeutic use of native GLP-1 is limited due to its short half-life. We recently developed a novel GLP-1 mimetics (supaglutide) by genetically engineering recombinant fusion protein production techniques. We demonstrated that this formulation possessed long-lasting GLP-1 actions and was effective in glycemic control in both type 1 and type 2 diabetes rodent models. Here, we investigated the effects of supaglutide in regulating energy homeostasis in obese mice. Mice were fed with high-fat diet (HFD) for 6 months to induce obesity and then subjected to supaglutide treatment (300 μg/kg, bi-weekly for 4 weeks), and placebo as control. Metabolic conditions were monitored and energy expenditure was assessed by indirect calorimetry (CLAMS). Cold tolerance test was performed to evaluate brown-adipose tissue (BAT) activities in response to cold challenge. Glucose tolerance and insulin resistance were evaluated by intraperitoneal glucose tolerance test and insulin tolerance tests. Liver and adipose tissues were collected for histology analysis. Expression of uncoupling protein 1(Ucp1) in adipose tissues was evaluated by Western blotting. We found that supaglutide treatment reduced body weight, which was associated with reduced food intake. Compared to the placebo control, supaglutide treatment improved lipid profile, i.e., significantly decreased circulating total cholesterol levels, declined serum triglyceride, and free fatty acid levels. Importantly, the intervention significantly reduced fatty liver, decreased liver triglyceride content, and concomitantly ameliorated liver injury exemplified by declined hepatic alanine aminotransferase (ALT) and aspartic transaminase (AST) content. Remarkably, supaglutide reduced hepatic lipid accumulation and altered morphometry in favor of small adipocytes in fat. This is consistent with the observation that supaglutide increased tolerance of the mice to cold environment associated with up-regulation of Ucp1 in the inguinal fat. Furthermore, supaglutide improved glucose tolerance, and insulin sensitivity in the obese mice suggesting improved glucose and energy homeostasis. Our findings suggest that supaglutide exerts beneficial effect on established obesity through reducing energy intake and is associated with brown remodeling of white adipose tissue.

(EX-4)2-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression

The Anorexic Effect of Ex4/Fc Through Glp-1 Receptor Activation in High-Fat Diet Fed Mice

A Novel Benzenediamine Derivative Fc98 Reduces Insulin Resistance in High Fat Diet-Induced Obese Mice by Suppression of Metaflammation

Exenatide Mitigates Inflammation and Hypoxia along with Improved Angiogenesis in Obese Fat Tissue.

Effect of GLP-1 receptor agonist on lipolysis in adipose tissue of obese mice and its underlying mechanism

Diet-Induced Adipose Tissue Inflammation and Hypoxia Are Reversed by GLP-1 Potentially Via Improved Microcirculation

The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4

Effect of Exendin-4 on Lipid Deposition in Skeletal Muscle of Diet-Induced Obese Mice and Its Underlying Mechanism

The Mab Against Adipocyte Fatty Acid-Binding Protein 2E4 Attenuates the Inflammation in the Mouse Model of High-Fat Diet-Induced Obesity Via Toll-Like Receptor 4 Pathway.

The Effect and Mechanism of TLR9/KLF4 in FFA-Induced Adipocyte Inflammation

Resistant dextrin reduces obesity and attenuates adipose tissue inflammation in high-fat diet-fed mice

Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration

Follistatin-Like 1: A Potential Mediator Of Inflammation In Obesity

Fibroblast Growth Factor 1 Ameliorates Adipose Tissue Inflammation and Systemic Insulin Resistance Via Enhancing Adipocyte Mtorc2/rictor Signal

FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity.

The Key Role of a Glucagon-Like Peptide-1 Receptor Agonist in Body Fat Redistribution

1938-P: GLP-1 Receptor Agonist Ameliorates Intramyocellular Lipid Deposition Without Weight Loss by Activating AMPK

FRI021 Adipocyte Subpopulations Regulate The Lipolytic Response And Inflammatory Cytokine Action In Obesity

GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions